基于68Ga-Pentixafor PET/CT的疗效评估及其在多发性骨髓瘤中的预后价值:与IMWG及18F-FDG疗效评估标准的比较
这项前瞻性单中心研究纳入40例初治多发性骨髓瘤患者,在基线和随访(中位7.2个月)时行68Ga-Pentixafor与18F-FDG PET/CT,提出基于68Ga-Pentixafor PET/CT的疗效评估标准并与IMWG及18F-FDG标准比较。68Ga-Pentixafor PET/CT阳性率高于18F-FDG PET/CT,且其疗效分类间无进展生存期存在显著差异。
要点
- 68Ga-Pentixafor PET/CT阳性率90%(36/40)高于18F-FDG PET/CT的67.5%(27/40),P=0.02。
- 按所提68Ga-Pentixafor标准,完全缓解组无进展生存期未达到、部分缓解组26.2个月、疾病进展组15.3个月,P=0.001。
- IMWG≥非常好的部分缓解者中,68Ga-Pentixafor阳性较阴性无进展生存期短(34.2个月 vs 未达到,P=0.056)。
核心结论
- 68Ga-Pentixafor PET/CT对多发性骨髓瘤治疗反应和预后提供更准确的评估,在IMWG和18F-FDG PET/CT标准之外提供有价值的信息。
研究设计与样本
- 前瞻性单中心研究,2021年2月至2023年4月招募40例初治多发性骨髓瘤患者,中位年龄56.5岁(IQR 45.25至63.75),男性24例。
- 基线和随访(中位7.2个月)时均行68Ga-Pentixafor与18F-FDG PET/CT,用所提68Ga-Pentixafor PET/CT标准评估疗效并与IMWG及18F-FDG PET/CT评估比较。
- 采用Kaplan-Meier生存曲线分析并比较无进展生存期和总生存期。
主要发现
- 68Ga-Pentixafor PET/CT阳性患者比例高于18F-FDG PET/CT:90%(36/40)vs 67.5%(27/40),P=0.02,因此对额外27.5%(11/40)病例的疗效进行了充分评估。
- 按所提68Ga-Pentixafor PET/CT标准,各疗效类别间无进展生存期存在显著差异:完全缓解组未达到、部分缓解组26.2个月、疾病进展组15.3个月,P=0.001。
- IMWG评估达≥非常好的部分缓解的患者中,68Ga-Pentixafor PET/CT阳性者较阴性者无进展生存期短(中位无进展生存期34.2个月 vs 未达到,P=0.056),而18F-FDG PET/CT未见显著差异(P=0.68)。
- 随访时18F-FDG阴性患者中,68Ga-Pentixafor结果不一致者较一致阴性者无进展生存期显著缩短(17.73个月 vs 未达到,P=0.010)。
关键数值与推荐
- 68Ga-Pentixafor PET/CT阳性率90%(36/40)vs 18F-FDG PET/CT 67.5%(27/40),P=0.02。
- 所提68Ga-Pentixafor PET/CT标准下完全缓解组无进展生存期未达到、部分缓解组26.2个月、疾病进展组15.3个月,P=0.001。
- IMWG≥非常好的部分缓解者中,68Ga-Pentixafor阳性组中位无进展生存期34.2个月 vs 阴性组未达到,P=0.056;18F-FDG PET/CT相应比较P=0.68。
- 18F-FDG阴性患者中,68Ga-Pentixafor不一致组无进展生存期17.73个月 vs 一致阴性组未达到,P=0.010。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: 68 Ga-Pentixafor PET/CT targets CXCR4 receptors and provides superior diagnostic accuracy in multiple myeloma (MM) compared with 18 F-FDG PET/CT. However, its role in response evaluation remains unexplored. We propose a 68 Ga-Pentixafor PET/CT-based response evaluation criterion and evaluate its utility compared with International Myeloma Working Group (IMWG) criteria and 18 F-FDG PET/CT-based response. PATIENTS AND METHODS: In this prospective single-center study, 40 treatment-naive myeloma patients were recruited between February 2021 and April 2023. Both 68 Ga-Pentixafor and 18 F-FDG PET/CT were performed at baseline and at follow-up (7.2 mo-median). Response to treatment was evaluated using the proposed 68 Ga-Pentixafor PET/CT criteria and compared with responses assessed by IMWG and 18 F-FDG PET/CT. Progression-free survival (PFS) and overall survival (OS) were analyzed and compared using Kaplan-Meier survival curves. RESULTS: Among the 40 newly diagnosed MM patients [median age: 56.5 years (IQR 45.25 to 63.75); 24 men], 68 Ga-Pentixafor PET/CT was positive in a greater proportion of patients than 18 F-FDG PET/CT [90% (36/40) vs. 67.5% (27/40); P =0.02] thus, adequately evaluated response in additional 27.5% (11/40) of cases. Using the proposed criteria for 68 Ga-Pentixafor PET/CT, significant differences in PFS were observed across response categories [complete response (CR)-not reached, partial response (PR)-26.2 mo, progressive disease (PD)-15.3 mo; P =0.001]. Among patients achieving ≥very good partial response (VGPR) as per IMWG, those with positive 68 Ga-Pentixafor PET/CT had shorter PFS compared with those with negative findings (median PFS: 34.2 mo vs. not reached; P =0.056), whereas no significant difference was noted with 18 F-FDG PET/CT ( P =0.68). In addition, on follow-up of patients with negative 18 F-FDG at the response, those with discordant 68 Ga-Pentixafor findings had significantly shorter PFS (17.73 mo vs. not reached; P =0.010) compared with those with concordant negative findings. CONCLUSIONS: 68 Ga-Pentixafor PET/CT offers a more accurate assessment of treatment response and prognosis in MM patients, adding valuable information beyond the IMWG and 18 F-FDG PET/CT-based criteria.
引用
- Kaur H, Kumar S, Watts A, et al. 68 Ga-Pentixafor PET/CT-Based Response Evaluation and its Prognostic Value in Multiple Myeloma: Comparison With IMWG and 18 F-FDG-Based Response. Clin Nucl Med. 2025. PMID: 40051087. doi:10.1097/RLU.0000000000005731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。